ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2019

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.

Ellen Q Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.